BR112014002133A2 - human tnf-specific bovine polyclonal antibody - Google Patents

human tnf-specific bovine polyclonal antibody

Info

Publication number
BR112014002133A2
BR112014002133A2 BR112014002133A BR112014002133A BR112014002133A2 BR 112014002133 A2 BR112014002133 A2 BR 112014002133A2 BR 112014002133 A BR112014002133 A BR 112014002133A BR 112014002133 A BR112014002133 A BR 112014002133A BR 112014002133 A2 BR112014002133 A2 BR 112014002133A2
Authority
BR
Brazil
Prior art keywords
polyclonal antibody
human tnf
specific bovine
bovine polyclonal
specific
Prior art date
Application number
BR112014002133A
Other languages
Portuguese (pt)
Inventor
S Fox Barbara
E Tracey Daniel
F Bostwick Eileen
D Schlehuber Lisa
S Quesenberry Michael
Original Assignee
Avaxia Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/402,527 external-priority patent/US20120213796A1/en
Application filed by Avaxia Biologics Inc filed Critical Avaxia Biologics Inc
Publication of BR112014002133A2 publication Critical patent/BR112014002133A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
BR112014002133A 2011-08-01 2012-08-01 human tnf-specific bovine polyclonal antibody BR112014002133A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161513872P 2011-08-01 2011-08-01
US13/402,527 US20120213796A1 (en) 2011-02-22 2012-02-22 Polyclonal antibody compositions
PCT/US2012/026112 WO2012141791A1 (en) 2011-02-22 2012-02-22 Polyclonal antibody compositions
PCT/US2012/049207 WO2013019889A2 (en) 2011-08-01 2012-08-01 Bovine polyclonal antibody specific for human tnf

Publications (1)

Publication Number Publication Date
BR112014002133A2 true BR112014002133A2 (en) 2017-02-21

Family

ID=47629904

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002133A BR112014002133A2 (en) 2011-08-01 2012-08-01 human tnf-specific bovine polyclonal antibody

Country Status (9)

Country Link
EP (1) EP2739650A4 (en)
JP (1) JP2014527957A (en)
CN (1) CN103917555A (en)
AU (1) AU2012290104A1 (en)
BR (1) BR112014002133A2 (en)
CA (1) CA2843315A1 (en)
IL (1) IL230748A0 (en)
WO (1) WO2013019889A2 (en)
ZA (1) ZA201401987B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012243284A1 (en) * 2011-02-22 2013-09-12 Avaxia Biologics, Inc. Polyclonal antibody compositions
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
GB201812262D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating proctitis
GB201812261D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating oral mucositis
WO2022103871A1 (en) * 2020-11-10 2022-05-19 Wyomingv Immune, Inc. Therapeutic compositions for the treatment of covid-19

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DK0610201T4 (en) * 1991-03-18 2008-02-04 Centocor Inc Monoclonal and chimeric antibodies specific for human tumor necrosis factor
RU2270030C2 (en) * 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNFα ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT
ES2382229T3 (en) * 2005-05-24 2012-06-06 Neovacs Process for the preparation of a stable immunogenic product comprising antigenic heterocomplexes of FNT alpha and a transporter protein
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
SG177577A1 (en) * 2009-08-07 2012-03-29 Emd Millipore Corp Methods for purifying a target protein from one or more impurities in a sample
AU2010306563B2 (en) * 2009-10-15 2013-11-28 Circle 33, Llc Antibody therapeutics with local activity in the digestive tract

Also Published As

Publication number Publication date
WO2013019889A2 (en) 2013-02-07
WO2013019889A3 (en) 2013-03-28
CA2843315A1 (en) 2013-02-07
EP2739650A2 (en) 2014-06-11
CN103917555A (en) 2014-07-09
JP2014527957A (en) 2014-10-23
AU2012290104A1 (en) 2014-02-13
IL230748A0 (en) 2014-03-31
ZA201401987B (en) 2017-03-27
EP2739650A4 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
FR23C1023I2 (en) ANTI-IL-36R ANTIBODIES
CO6801647A2 (en) Formulation for anti-α4β7 antibody
CO6801648A2 (en) Formulation for anti-α4β7 antibody
CO6811812A2 (en) Anti-b7-h3 antibody
BR112013012782A2 (en) human antibodies to glucagon receptor
BR112014012137A2 (en) anti-fgfr2 antibodies and their uses
DK2683406T3 (en) ANTI-CD40 ANTIBODIES AND USES THEREOF
DK3275892T3 (en) PRÆFUSIONS-RSV F ANTIGENS
SMT201600193B (en) NEW ANTI-DR5 ANTIBODY
BR112012030311A2 (en) antibody
DK3091029T3 (en) Anti-IL13 antibody formulations
DK2580243T3 (en) ANTIBODIES AGAINST HUMAN CD38
CO6920257A2 (en) Fusion proteins to treat metabolic disorders
DK3178851T3 (en) ANTI-CD40 ANTIBODIES
DK2521736T3 (en) Humanized antibodies
CO7020866A2 (en) Therapeutic peptides
CR20140127A (en) ANTI-ABTCR ANTIBODY
DK3381943T3 (en) ANTI-KIT ANTIBODIES AND USES THEREOF
DK2668210T3 (en) ANTI-KIT ANTIBODIES AND USES THEREOF
CO6801637A2 (en) Antibody formulations
CO6791565A2 (en) Anti-notch1 antibodies
DK3202789T3 (en) Anti-VLA-4 antibodies
DK2705144T4 (en) POLYPEPTIDE
BR112013017961A2 (en) triplet antigen for treponema pallidum
BR112014002133A2 (en) human tnf-specific bovine polyclonal antibody

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]